These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
91 related articles for article (PubMed ID: 8084811)
1. [Function of platelets in patients with occlusive atherosclerotic arterial disease of the lower extremities]. Psuja P; Zozulińska M; Lewandowski K; Turowiecka Z; Pioruńska-Stolzmann M; Majewski W; Patelski J; Zawilska K Pol Arch Med Wewn; 1994 May; 91(5):349-55. PubMed ID: 8084811 [TBL] [Abstract][Full Text] [Related]
2. [Chronic peripheral arterial occlusive disease, platelet glycoproteins GPIIb-IIIa and GP Ib-IX, plasma von Willebrand factor and plasma fibrinogen concentrations in patients with type 2 diabetes mellitus]. Gosk-Bierska I; Adamiec R; Doskocz W; Ciosek W Pol Arch Med Wewn; 2000; 103(3-4):139-45. PubMed ID: 11236240 [TBL] [Abstract][Full Text] [Related]
3. Influence of lipids metabolism on platelet activation in vivo. Sano T; Motomiya T; Yamazaki H Thromb Res; 1983 Sep; 31(5):675-84. PubMed ID: 6417824 [TBL] [Abstract][Full Text] [Related]
4. The impact of peripheral arterial disease on circulating platelets. McBane RD; Karnicki K; Miller RS; Owen WG Thromb Res; 2004; 113(2):137-45. PubMed ID: 15115669 [TBL] [Abstract][Full Text] [Related]
5. Flow cytometric assessment of platelet function in patients with peripheral arterial occlusive disease. Galt SW; McDaniel MD; Ault KA; Mitchell J; Cronenwett JL J Vasc Surg; 1991 Dec; 14(6):747-55; discussion 755-6. PubMed ID: 1720468 [TBL] [Abstract][Full Text] [Related]
6. Role of von Willebrand factor in arterial thrombosis. Studies in normal and von Willebrand disease pigs. Nichols TC; Bellinger DA; Reddick RL; Read MS; Koch GG; Brinkhous KM; Griggs TR Circulation; 1991 Jun; 83(6 Suppl):IV56-64. PubMed ID: 2040072 [TBL] [Abstract][Full Text] [Related]
7. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera. Michiels JJ; Berneman Z; Schroyens W; Finazzi G; Budde U; van Vliet HH Semin Thromb Hemost; 2006 Sep; 32(6):589-604. PubMed ID: 16977569 [TBL] [Abstract][Full Text] [Related]
8. A prospective study of peripheral occlusive arterial disease in diabetes. IV. Platelet and plasma functions. Kazmier FJ; Bowie EJ; O'Fallon WM; Zimmerman BR; Osmundson PJ; Palumbo PJ Mayo Clin Proc; 1981 Apr; 56(4):243-53. PubMed ID: 6971378 [TBL] [Abstract][Full Text] [Related]
9. Defective interaction between von Willebrand factor and platelet glycoprotein Ib--a familial study of peripheral arterial occlusive disease. Kauhanen P; Beer JH; Lassila R Thromb Haemost; 1997 May; 77(5):849-55. PubMed ID: 9184391 [TBL] [Abstract][Full Text] [Related]
10. Platelet half-life, plasma thromboxane B2 and circulating endothelial-cells in peripheral vascular disease. Sinzinger H; Fitscha P; Peskar BA Angiology; 1986 Feb; 37(2):112-8. PubMed ID: 3954150 [TBL] [Abstract][Full Text] [Related]
11. von Willebrand factor binds to platelets and induces aggregation in platelet-type but not type IIB von Willebrand disease. Miller JL; Kupinski JM; Castella A; Ruggeri ZM J Clin Invest; 1983 Nov; 72(5):1532-42. PubMed ID: 6415113 [TBL] [Abstract][Full Text] [Related]
12. [Platelet activation in young men after myocardial infarction: its relation to metabolic coronary risk factors]. Elikowski W; Zozulińska M; Psuja P; Turowiecka Z; Przybył L; Zawilska K Kardiol Pol; 1992 Jun; 36(6):341-6. PubMed ID: 1507741 [TBL] [Abstract][Full Text] [Related]
13. Detection of prethrombotic states in patients with atherosclerotic lesions. Breddin K Semin Thromb Hemost; 1986 Apr; 12(2):110-23. PubMed ID: 3526555 [No Abstract] [Full Text] [Related]
14. Platelet resistance to prostacyclin. Enhancement of the antiaggregatory effect of prostacyclin by pentoxifylline. Manrique RV; Manrique V Angiology; 1987 Feb; 38(2 Pt 1):101-8. PubMed ID: 3030162 [TBL] [Abstract][Full Text] [Related]
15. Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA. McCabe DJ; Harrison P; Mackie IJ; Sidhu PS; Lawrie AS; Purdy G; Machin SJ; Brown MM Platelets; 2005 Aug; 16(5):269-80. PubMed ID: 16011977 [TBL] [Abstract][Full Text] [Related]
16. Abnormalities of cholesterol-phospholipid composition in platelets and low-density lipoproteins of human hyperbetalipoproteinemia. Shattil SJ; Bennett JS; Colman RW; Cooper RA J Lab Clin Med; 1977 Feb; 89(2):341-53. PubMed ID: 188956 [TBL] [Abstract][Full Text] [Related]
17. [Platelet half-life in patients with primary hyperlipoproteinemia type IIa, IIb, and IV according to Fredrickson with and without clinical signs of atherosclerosis]. Jäger E; Sinzinger H; Widhalm K; Kaliman J; Höfer R Wien Klin Wochenschr; 1982 Sep; 94(16):421-5. PubMed ID: 7147981 [TBL] [Abstract][Full Text] [Related]
18. Serum Lp(a) lipoprotein levels in patients with atherosclerotic occlusive disease of the lower extremities. Dionyssiou-Asteriou A; Papastamatiou M; Vatalas I; Bastounis E Eur J Vasc Endovasc Surg; 2000 Jul; 20(1):57-60. PubMed ID: 10906299 [TBL] [Abstract][Full Text] [Related]
19. The effect of clopidogrel, aspirin and both antiplatelet drugs on platelet function in patients with peripheral arterial disease. Jagroop IA; Matsagas MI; Geroulakos G; Mikhailidis DP Platelets; 2004 Mar; 15(2):117-25. PubMed ID: 15154604 [TBL] [Abstract][Full Text] [Related]